Related Experiment Video

Updated: Jun 24, 2026

Isolation, Transfection, and Culture of Primary Human Monocytes
09:13

Isolation, Transfection, and Culture of Primary Human Monocytes

Published on: December 16, 2019

Altered iron metabolism in children with human immunodeficiency virus disease

Ellen Butensky James1, Paul Harmatz, Marion Lee

  • 1Department of Gastroenterology and Nutrition, Children's Hospital & Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA. ejames@mail.cho.org

Pediatric Hematology and Oncology
|March 27, 2009
PubMed

Insights

Altered iron metabolism is common in children with human immunodeficiency virus (HIV) disease, even with modern treatments. Further research is needed to identify children at risk for these iron metabolism changes.

Area of Science:

  • Pediatric infectious diseases
  • Hematology
  • Nutritional science

Background:

  • Altered iron metabolism is prevalent in children with human immunodeficiency virus (HIV) disease.
  • These metabolic alterations remain understudied in pediatric HIV populations.

Purpose of the Study:

  • To investigate the prevalence and types of iron metabolism alterations in children with HIV disease.
  • To classify anemia in these children as iron-deficiency anemia or anemia of chronic disease.

Main Methods:

  • Laboratory evaluation of 26 children diagnosed with HIV disease.
  • Assessment for anemia and classification of its type.

Main Results:

  • Half of the children exhibited altered iron metabolism.
  • Specific findings included iron deficiency (6 children), hyperferritinemia (4 children), and combined hyperferritinemia with iron deficiency (3 children).

Conclusions:

  • Alterations in iron metabolism are frequent in children with HIV, persisting even during the highly active antiretroviral therapy (HAART) era.
  • Further investigation is crucial to identify children susceptible to these iron metabolism disturbances.
Abstract

More Related Videos

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...